The introduction of early breast cancer screening and advanced neoadjuvant and adjuvant anti‐HER2 treatments have significantly improved the pCR rates and reduced mortality rates in patients with HER2‐positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.